• Kyodo

  • SHARE

Japan will receive 150 million doses of U.S. pharmaceutical giant Novavax Inc.’s COVID-19 vaccine from as early as the beginning of 2022, the health ministry said Tuesday.

The ministry said it has signed a deal with Japan’s Takeda Pharmaceutical Co., which will handle manufacturing and distribution of the Novavax vaccine in Japan. Takeda and Novavax are currently developing the vaccine, aiming to use it as a booster and also to make it effective against coronavirus variants.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)